In this meta-analysis of RCTs, we found that adding docetaxel to SOC treatment in patients with prostate cancer who are in otherwise good health with a PSA level of less than 4 ng/mL and a Gleason score of 8 to 10 was associated with a significant reduction in PCSM and therefore has the potential to improve prognosis. This evidence concerns the gene KLK3 and prostate cancer.